Last checked at 7 Apr 2017 07:00
7 April 2017
Microsaic Systems plc
("Microsaic", "Microsaic Systems" or the "Company")
Microsaic signs amended agreement with Global Partner
Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry instruments, announces that it has signed an amendment to its Research Collaboration Agreement with a long standing global partner. The amended agreement is a precursor to future collaboration in the area of bio-processing.
Interim Chairman, Eric Yeatman commented:
"We are delighted to sign this agreement with one of the foremost players in the global market for scientific instrumentation, which is in line with the Company's strategy to focus on application areas in biopharma."
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Enquiries: | |
Microsaic Systems plc Jim Ramage, CEO Bevan Metcalf, FD | +44 (0) 1483 751577 |
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson Liz Yong
| +44 (0)20 7496 3000 |
Citigate Dewe Rogerson (Financial PR) Mark Swallow, Marine Perrier
| +44 (0)20 7282 2948/1068 |
About Microsaic Systems
Microsaic Systems plc is a high technology company developing chip-based, bench-top mass spectrometry ("MS") instruments that are designed to improve the efficiency of Pharma R&D. MS is an analytical technique of choice for biochemists across many industry sectors.
Microsaic aims to bring routine MS analysis to the pharmaceutical scientist, providing powerful methods of analysis to enable earlier decision making relating to product identification, purity and bioactivity.
The Company is working with established global companies in preparative and purification science with expertise in Pharma and life sciences to co-develop new, integrated and optimised, application-specific, solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines.
The Microsaic 4000 MiD®, single quadrupole, is the world's smallest MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. The Company is also developing new MS systems, based on its patented chip technologies, to address further areas of emerging need in Pharma R&D.
Microsaic Systems was established in 2001 by a team including founders from Imperial College London, and was admitted to AIM in 2011 (ticker: MSYS).
www.microsaic.com